Literature DB >> 18565854

In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.

Ryosei Nishimura1, Jeanette Baker, Andreas Beilhack, Robert Zeiser, Janelle A Olson, Emanuela I Sega, Mobin Karimi, Robert S Negrin.   

Abstract

Cytokine-induced killer (CIK) cells are ex vivo-expanded T lymphocytes expressing both natural killer (NK)- and T-cell markers. CIK cells are cytotoxic against autologous and allogeneic tumors. We previously showed that adoptive transfer of allogeneic CIK cells in a murine model caused minimal graft-versus-host disease (GVHD). However, the precise mechanism of reduced GVHD is not fully understood. Therefore, we evaluated the trafficking and survival of luciferase-expressing CIK cells in an allogeneic bone marrow transplant model. The initial trafficking patterns of CIK cells were similar to conventional T cells that induced GVHD; however, CIK cells infiltrated GVHD target tissues much less and transiently. CIK cells accumulated and persisted in tumor sites, resulting in tumor eradication. We evaluated different properties of CIK cells compared with conventional T cells, demonstrating a slower division rate of CIK cells, higher susceptibility to apoptosis, persistent increased expression of interferon gamma (IFN-gamma), and reduced acquisition of homing molecules required for entry of cells into inflamed GVHD target organs that lack expression of NKG2D ligands recognized by CIK cells. Due to these properties, allogeneic CIK cells had reduced expansion and caused less tissue damage. We conclude that CIK cells have the potential to separate graft-versus-tumor effects from GVHD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18565854      PMCID: PMC2532819          DOI: 10.1182/blood-2007-06-092817

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

2.  Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts.

Authors:  Y C Linn; L C Lau; Kam M Hui
Journal:  Br J Haematol       Date:  2002-01       Impact factor: 6.998

Review 3.  The role of the NKG2D receptor for tumor immunity.

Authors:  Jérôme D Coudert; Werner Held
Journal:  Semin Cancer Biol       Date:  2006-07-08       Impact factor: 15.707

4.  Increased apoptosis of peripheral blood T cells following allogeneic hematopoietic cell transplantation.

Authors:  M T Lin; L H Tseng; H Frangoul; T Gooley; J Pei; A Barsoukov; Y Akatsuka; J A Hansen
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

5.  Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells.

Authors:  Yong-Guang Yang; Jin Qi; Min-Guang Wang; Megan Sykes
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

6.  Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation.

Authors:  J C Alvarnas; Y C Linn; E G Hope; R S Negrin
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

Review 7.  Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice.

Authors:  Michael R Verneris; Jeanette Baker; Matthias Edinger; Robert S Negrin
Journal:  J Clin Immunol       Date:  2002-05       Impact factor: 8.317

8.  Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging.

Authors:  Matthias Edinger; Yu-An Cao; Michael R Verneris; Michael H Bachmann; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

9.  The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model.

Authors:  Tatsuya Fujioka; Yuki Taniguchi; Tomoki Masuda; Sumiyuki Nishida; Kazuhiro Ikegame; Manabu Kawakami; Akihiro Tsuboi; Naoki Hosen; Masaki Murakami; Yusuke Oji; Yoshihiro Oka; Haruo Sugiyama; Ichiro Kawase; Hiroyasu Ogawa
Journal:  Transpl Immunol       Date:  2003 Apr-Jun       Impact factor: 1.708

10.  Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Petra Hoffmann; Joerg Ermann; Matthias Edinger; C Garrison Fathman; Samuel Strober
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

View more
  67 in total

1.  IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy.

Authors:  Mike W Helms; Jennifer A Prescher; Yu-An Cao; Steven Schaffert; Christopher H Contag
Journal:  Cancer Immunol Immunother       Date:  2010-06-09       Impact factor: 6.968

2.  The Efficacy of CIK-Based Immunotherapies for Advanced Solid Tumors.

Authors:  Hongjin Chu; Fengcai Du; Lixin Jiang; Zhixin Wang; Zhaohua Gong; Peiwen Lian; Peng Li; Jian Chen
Journal:  Technol Cancer Res Treat       Date:  2016-07-19

3.  Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease.

Authors:  Yi Zhang; Ashley R Sandy; Jina Wang; Vedran Radojcic; Gloria T Shan; Ivy T Tran; Ann Friedman; Koji Kato; Shan He; Shuaiying Cui; Elizabeth Hexner; Dale M Frank; Stephen G Emerson; Warren S Pear; Ivan Maillard
Journal:  Blood       Date:  2010-09-24       Impact factor: 22.113

4.  Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".

Authors:  Andreas A Hombach; Gunter Rappl; Hinrich Abken
Journal:  Mol Ther       Date:  2013-08-28       Impact factor: 11.454

5.  Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.

Authors:  I Pizzitola; F Anjos-Afonso; K Rouault-Pierre; F Lassailly; S Tettamanti; O Spinelli; A Biondi; E Biagi; D Bonnet
Journal:  Leukemia       Date:  2014-02-07       Impact factor: 11.528

6.  NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.

Authors:  Mobin A Karimi; Jerrod L Bryson; Lee P Richman; Andrew D Fesnak; Theresa M Leichner; Atsushi Satake; Robert H Vonderheide; David H Raulet; Ran Reshef; Taku Kambayashi
Journal:  Blood       Date:  2015-03-18       Impact factor: 22.113

7.  In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells.

Authors:  Céline Leboeuf; Laurent Mailly; Tao Wu; Gaetan Bour; Sarah Durand; Nicolas Brignon; Christophe Ferrand; Christophe Borg; Pierre Tiberghien; Robert Thimme; Patrick Pessaux; Jacques Marescaux; Thomas F Baumert; Eric Robinet
Journal:  Mol Ther       Date:  2013-12-06       Impact factor: 11.454

8.  A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma.

Authors:  Xiaozhou Yu; Hua Zhao; Liang Liu; Shui Cao; Baozhu Ren; Naining Zhang; Xiumei An; Jinpu Yu; Hui Li; Xiubao Ren
Journal:  J Clin Immunol       Date:  2013-12-15       Impact factor: 8.317

9.  CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD.

Authors:  Suparna Dutt; Jeanette Baker; Holbrook E Kohrt; Neeraja Kambham; Mrinmoy Sanyal; Robert S Negrin; Samuel Strober
Journal:  Blood       Date:  2011-01-14       Impact factor: 22.113

Review 10.  Cytokine-induced NK-like T cells: from bench to bedside.

Authors:  Yeh Ching Linn; Kam M Hui
Journal:  J Biomed Biotechnol       Date:  2010-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.